Australia: Enveric, FSD Pharma, Psyence & Others Advance Businesses
Enveric Biosciences (NASDAQ: ENVB) has created an Australia-based subsidiary, Enveric Therapeutics, to support its next-generation psychedelics program for anxiety disorders.
FSD Pharma Inc.’s (NASDAQ: HUGE) Australian business, FSD Pharma Australia, has been approved by the Alfred Ethics Committee to begin a Phase 1 clinical trial of next-gen drug candidate Lucid-201 for cases of Major Depressive Disorder.
Psyence Group Inc. (OTCMKTS: PSYGF) partnered with iNGENū on a Phase 2b clinical trial on psilocybin for palliative care.
Emyria Ltd. is working with the University of Western Australia to expand its MDMA analogs library.
Study Sheds Light On How A Brain On Ayahuasca Looks
A new study, led by a group at Imperial College London, revealed the most advanced-to-date brain images of the effects of the psychedelic compound DMT.
The trial monitored the brain activity of 20 healthy volunteers receiving either a 20mg DMT injection or a placebo through functional magnetic resonance imaging (fMRI) and electroencephalography (EEG) before, during and after the psychedelic session.
The brain’s normal structures change their standard hierarchical modes towards a more fluid communication and connectivity between regions related to imagination, language, memory and …
